Last reviewed · How we verify

NCT07025577

A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

Completed Phase 1 Last updated 10 September 2025
What this trial tests

Phase 1 trial testing Immunoglobulin G in Healthy Participants in 82 participants. Completed in 3 September 2025.

Timeline
2 June 2025
Primary endpoint
8 August 2025
3 September 2025

Quick facts

Lead sponsorGenentech, Inc.
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment82
Start date2 June 2025
Primary completion8 August 2025
Estimated completion3 September 2025
Sites3 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Genentech, Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the safety and tolerability of SC administration of IgG in healthy participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Immunoglobulin G

Trials testing the same drug.

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

Other Genentech, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07025577.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing